JP2008508360A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508360A5
JP2008508360A5 JP2007524924A JP2007524924A JP2008508360A5 JP 2008508360 A5 JP2008508360 A5 JP 2008508360A5 JP 2007524924 A JP2007524924 A JP 2007524924A JP 2007524924 A JP2007524924 A JP 2007524924A JP 2008508360 A5 JP2008508360 A5 JP 2008508360A5
Authority
JP
Japan
Prior art keywords
alkylene
compound
carboxylic acid
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007524924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508360A (ja
JP5046930B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/027479 external-priority patent/WO2006015357A2/en
Publication of JP2008508360A publication Critical patent/JP2008508360A/ja
Publication of JP2008508360A5 publication Critical patent/JP2008508360A5/ja
Application granted granted Critical
Publication of JP5046930B2 publication Critical patent/JP5046930B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007524924A 2004-08-02 2005-08-02 Ａ２ａアゴニスト活性を有する修飾５’−リボース基を備えた２−プロピニルアデノシン類似体 Expired - Fee Related JP5046930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59801804P 2004-08-02 2004-08-02
US60/598,018 2004-08-02
PCT/US2005/027479 WO2006015357A2 (en) 2004-08-02 2005-08-02 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity

Publications (3)

Publication Number Publication Date
JP2008508360A JP2008508360A (ja) 2008-03-21
JP2008508360A5 true JP2008508360A5 (enExample) 2012-02-09
JP5046930B2 JP5046930B2 (ja) 2012-10-10

Family

ID=35787921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007524924A Expired - Fee Related JP5046930B2 (ja) 2004-08-02 2005-08-02 Ａ２ａアゴニスト活性を有する修飾５’−リボース基を備えた２−プロピニルアデノシン類似体

Country Status (10)

Country Link
US (3) US7605143B2 (enExample)
EP (2) EP2266994B1 (enExample)
JP (1) JP5046930B2 (enExample)
CN (1) CN101068825B (enExample)
AU (1) AU2005267706B2 (enExample)
CA (1) CA2576826C (enExample)
NZ (2) NZ553288A (enExample)
SG (1) SG155182A1 (enExample)
WO (1) WO2006015357A2 (enExample)
ZA (1) ZA200701021B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
AU2001280946A1 (en) * 2000-08-01 2002-02-13 University Of Virginia Patent Foundation Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
NZ532062A (en) 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
EP1496911B1 (en) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
GB0622826D0 (en) * 2006-11-15 2006-12-27 Acurepharma Ab Novel amides acting on the adenosine receptors
JP2008266143A (ja) * 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8293720B2 (en) * 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
JP2011513493A (ja) 2008-03-10 2011-04-28 コーネル ユニバーシティー 血液脳関門透過性の調節方法
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
EP2306971B1 (en) 2008-07-03 2015-02-25 University Of Virginia Patent Foundation Unit dosage of apadenoson
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US8263762B2 (en) * 2009-06-30 2012-09-11 Dogwood Pharmaceuticals, Inc. Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
WO2011143442A1 (en) * 2010-05-12 2011-11-17 Trovis Pharmaceuticals, Llc. A method of treating multiple sclerosis with adenosine receptor agonists
US8940751B2 (en) 2010-09-13 2015-01-27 Advinus Therapeutics Private Limited Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
CA2819648C (en) 2010-12-03 2018-05-01 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
IN2015DN00538A (enExample) 2012-08-01 2015-06-26 Lewis And Clark Pharmaceuticals Inc
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
US9738679B2 (en) 2013-03-15 2017-08-22 Epizyme, Inc. Methods of synthesizing substituted purine compounds
KR102201319B1 (ko) 2014-01-14 2021-01-11 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
EP2907815B1 (en) 2014-02-12 2023-12-06 Samsung Electronics Co., Ltd. Condensed cyclic compound and organic light-emitting device including the same
US11672167B2 (en) 2015-03-13 2023-06-06 Samsung Electronics Co., Ltd. Organometallic compound and organic light-emitting device including the same
KR102429871B1 (ko) 2015-03-13 2022-08-05 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
US20170047532A1 (en) 2015-08-13 2017-02-16 Samsung Electronics Co., Ltd. Organometallic compound, organic light-emitting device including the organometallic compound, and diagnosis composition including the organometallic compound
EP3133078B1 (en) 2015-08-18 2019-01-30 Samsung Electronics Co., Ltd. Organometallic compound and organic light-emitting device including the same
JP2022538409A (ja) * 2019-06-21 2022-09-02 アカデミー オブ ミリタリー メディカル サイエンシズ アデノシン化合物、その医薬的に許容可能な塩又はその立体異性体及びその使用
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
BR112023023996A2 (pt) 2021-05-18 2024-01-30 Adovate Llc Xantinas de piridil contendo amida cíclica como antagonistas de a2b
CA3231766A1 (en) 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methods of treating ocular inflammatory diseases

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892777A (en) * 1968-05-01 1975-07-01 Hoffmann La Roche Substituted benzylethylenedicarbamates
CH608236A5 (enExample) * 1974-01-22 1978-12-29 Wuelfing J A Fa
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4824660A (en) * 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
US5070877A (en) * 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5122880A (en) * 1989-05-29 1992-06-16 Canon Kabushiki Kaisha Electronic still camera with lessened power consumption
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
USRE36494E (en) * 1990-02-20 2000-01-11 Discovery Therapeutics, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
SG80526A1 (en) 1990-09-25 2001-05-22 Rhone Poulenc Rorer Int Compounds having antihypertensive and anti- ischemic properies
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
FR2754260B1 (fr) * 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US6202321B1 (en) * 1997-04-02 2001-03-20 Paul B. Soucy Drying apparatus for coffee beans and similar crops
WO1998047509A1 (en) 1997-04-18 1998-10-29 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AU732505B2 (en) 1997-06-17 2001-04-26 Altarex Medical Corp. Therapeutic composition and method of treatment
WO1998057651A1 (en) 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
US6020339A (en) * 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6034089A (en) * 1997-10-03 2000-03-07 Merck & Co., Inc. Aryl thiophene derivatives as PDE IV inhibitors
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
EP1044004A1 (en) 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
NZ508314A (en) 1998-06-02 2004-03-26 Osi Pharm Inc Pyrrolo[2,3d]pyrimidine compositions and their use
AU4675699A (en) 1998-06-08 1999-12-30 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1313861A (zh) 1998-06-23 2001-09-19 葛兰素集团有限公司 2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
AU5879299A (en) 1998-10-16 2000-05-08 Monaghan, Sandra Marina Adenine derivatives
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
ES2215609T3 (es) * 1999-02-01 2004-10-16 University Of Virginia Patent Foundation Composiciones para el tratamiento de la respuesta inflamatoria.
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
WO2000072799A2 (en) 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) * 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
AU2001280946A1 (en) 2000-08-01 2002-02-13 University Of Virginia Patent Foundation Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
WO2002020539A1 (en) * 2000-09-08 2002-03-14 Toa Eiyo Ltd. Adenosine derivatives and use thereof
GB0022695D0 (en) * 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
CN1535161A (zh) 2001-05-25 2004-10-06 腺苷A2a受体激动剂和抗胆碱能试剂在联合用药治疗气道阻塞性疾病中的应用
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
EP1496911B1 (en) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
DK1658291T3 (da) * 2003-08-25 2013-10-28 Dogwood Pharmaceuticals Inc Substituerede 8-heteroaryl xanthiner
AU2005231440B9 (en) 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
MX2007003271A (es) * 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20070032450A1 (en) * 2005-08-02 2007-02-08 Rieger Jayson M New compositions and methods for the treatment of inflammation
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8293720B2 (en) * 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Similar Documents

Publication Publication Date Title
JP2008508360A5 (enExample)
CA2460911A1 (en) 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
JP6227707B2 (ja) Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。
JP2007536241A5 (enExample)
AR063351A1 (es) DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA.
JP2008517983A5 (enExample)
JP2012508249A5 (enExample)
RU2009104764A (ru) Производные пурина, как антангонисты a2a
JP2013525318A5 (enExample)
BRPI0605921B1 (pt) Compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
RU2008145701A (ru) Производные пурина для применения в качестве агонистов аденозинового рецептора a2a
JP2008518999A5 (enExample)
RU2010101611A (ru) Полициклические производные гуанина и способы их применения
RU2015135005A (ru) Ингибиторы ras и их применение
JP2008526996A5 (enExample)
AR064471A1 (es) Macrociclos inhibidores selectivos del factor de coagulacion viia, composiciones farmaceuticas que los comprenden y uso de los mismos como agentes anticoagulantes.
JP2009084270A5 (enExample)
WO2005107463A1 (en) Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
TW200745058A (en) MMP-13 selective inhibitors
JP2017504595A5 (enExample)
JP2010524947A5 (enExample)
JP2007509103A5 (enExample)
HRP20170964T1 (hr) Tiadiazolidindioni kao inhibitori gsk-3
JP2005506298A5 (enExample)
JP2006512306A (ja) アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途